FDA
-
-
-
-
-
-
-
ORYZON Announces First‑Patient‑In (FPI) in RESTORE Phase Ib Trial of Iadademstat in Sickle Cell Disease
-
-
-
-
-
-
-
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat
-
-
-
-
-
-
-
ORYZON Raises €30 Million in Capital Increase
-
-
-
-
-
-
-
ORYZON to Provide Corporate Progress Updates at Several Events in January-February
-
-
-
-
-
-
-
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat with Additional “Decision to Grant” Communications
-
-
-
-
-
-
-
ORYZON to Provide Corporate Progress Updates at Several Events in June
-
-
-
-
-
-
-
ORYZON to Provide Corporate Progress Updates at Several Events in February-March
-
326,596 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

